Ehlers, who served as the company’s inaugural CEO, will shift his focus toward long-term scientific strategy and board governance. His successor, Rosan, maintains his duties as Chief Financial Officer and Chief Business Officer, bridging the gap between current operations and the ongoing search for a permanent successor to the chief executive office.

The firm currently centers its clinical ambitions on ACDN-01, a candidate targeting Stargardt disease. With the RNA exon editing platform now established, the company’s strategy pivots toward executing its broader pipeline, which spans retinal, renal, and neurological conditions. Rosan’s appointment signals a push to stabilize the company’s business operations while maintaining momentum in clinical development.